Mounjaro (tirzepatide) has arrived in Brazil, offering a new dual-action approach to diabetes and weight management. Here's how it compares to the well-established Ozempic (semaglutide) for Brazilian patients.
What Makes Mounjaro Different from Ozempic in Brazil Right Now
Mounjaro received ANVISA approval and entered the Brazilian market as the first dual GIP/GLP-1 receptor agonist available in the country. Ozempic (semaglutide) has been available in Brazil since 2019 and is prescribed for type 2 diabetes, while Mounjaro targets the same patient population with a different mechanism of action. The active ingredient in Mounjaro is tirzepatide, which acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, whereas Ozempic only targets GLP-1 receptors. Both medications are injectables administered weekly under the skin, but they come in different pen presentations and dosing schedules.
The Clinical Numbers: What Studies Show About Tirzepatide vs. Semaglutide
The SURPASS clinical trial program showed that Mounjaro reduced HbA1c by up to 2.4% at the highest dose (15 mg), with average weight losses of 12-22% of body weight depending on the dose and study duration. The SUSTAIN trial program for Ozempic showed HbA1c reductions of up to 1.8% at the highest available dose (2 mg), with average weight losses of approximately 6-10% of body weight. In head-to-head trials comparing the two medications, tirzepatide demonstrated superior results in both blood sugar control and weight reduction at every dose level tested. Both medications showed reduction in cardiovascular risk markers, though the long-term cardiovascular outcome trials studied different populations and endpoints.
How Each Medication Works in Your Body
GLP-1 receptor agonists like semaglutide work by mimicking the incretin hormone that stimulates insulin release after meals, slows gastric emptying, and reduces appetite signals in the brain. Mounjaro's dual action adds GIP receptor activation, which may enhance the glucose-lowering effect and contribute to the greater weight loss observed with tirzepatide. Both medications require dose escalation over time to reach therapeutic levels, with Mounjaro offering six dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg) and Ozempic offering four (0.25, 0.5, 1, 2 mg). Neither medication should be used by people with type 1 diabetes or those with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Side Effects and What Brazilian Patients Should Watch For
The most common side effects for both Mounjaro and Ozempic are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which tend to occur during dose escalation.
- Injection site reactions can occur with both medications, though they are generally mild and temporary
- Both medications carry warnings for potential pancreas inflammation (pancreatitis) and gallbladder problems, though these occur rarely in clinical practice
- Patients should report persistent or severe symptoms to their healthcare provider promptly
Your doctor can help you manage these side effects and determine if dose adjustments are necessary.
Availability, Cost, and How to Get Mounjaro in Brazil
Mounjaro is currently available in Brazilian pharmacies with a medical prescription, and the price point reflects its status as a newer medication with no generic alternatives yet available. Ozempic has been on the Brazilian market longer and may have more established reimbursement pathways through private health insurance, though coverage varies by operator and plan type. Neither medication is currently available through the public healthcare system (SUS) in Brazil, meaning patients pay out of pocket or through private insurance. Patients should purchase both medications only from licensed pharmacies with proper cold chain storage and valid prescriptions, avoiding unregulated online sources. For more details on accessing these medications, OzemBlog provides helpful guidance on navigating prescription requirements.
Who Might Benefit More from Each Option
Patients with type 2 diabetes who have not achieved adequate blood sugar control with Ozempic at the maximum dose may be candidates for switching to Mounjaro under medical supervision. Individuals with obesity or overweight plus type 2 diabetes may experience more significant weight loss with Mounjaro based on clinical trial data, though individual responses vary. Patients with a strong preference for a wider range of dose options may find Mounjaro's six available strengths allow for more granular dose titration. OzemBlog offers additional resources comparing these treatment options to help you have an informed conversation with your doctor.
The choice between Mounjaro and Ozempic ultimately depends on your individual health profile, treatment goals, and budget. Both represent significant advances in diabetes care, and having more options available in Brazil gives patients and healthcare providers greater flexibility in managing type 2 diabetes. Discuss these factors with your doctor to determine which medication aligns best with your needs. OzemBlog continues to monitor developments in this space and provide updates for patients considering these treatment paths.
FAQ
Can Mounjaro be used for weight loss in Brazil?
Mounjaro is approved in Brazil for type 2 diabetes treatment. While weight loss is a documented effect of the medication, its use specifically for weight loss should be discussed with a healthcare provider who can assess your individual situation and determine the most appropriate treatment plan.
What is the main difference between Mounjaro and Ozempic?
The main difference lies in their mechanisms of action. Mounjaro (tirzepatide) acts on both GIP and GLP-1 receptors, while Ozempic (semaglutide) only targets GLP-1 receptors. This dual action in Mounjaro may contribute to greater efficacy in blood sugar control and weight reduction based on clinical trial results.
Is Mounjaro more effective than Ozempic for diabetes control?
Clinical trials comparing the two medications showed that tirzepatide (Mounjaro) demonstrated superior results in both HbA1c reduction and weight loss at every dose level tested. However, individual responses to medications vary, and effectiveness depends on many factors specific to each patient.
Are these medications covered by health insurance in Brazil?
Coverage varies by insurance operator and plan type. Ozempic has been on the market longer and may have more established reimbursement pathways. Neither medication is currently available through the public healthcare system (SUS). Patients should check with their insurance provider regarding specific coverage for their plan.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Never miss a dose and track everything
Injection reminders, a dose history and a side-effects diary — all organized to bring to your appointment.
or download the app
